20. “An in vivo duck hepatitis B virus model recapitulates key aspects of nucleicacid polymer treatment outcomes in chronic hepatitis B patients.” Antiviral Research (2024), 224, 105835

19. “Synthesis and evaluation of highly potent HBV capsid assembly modulators (CAMs).” Bioorganic Chemistry (2023), 141, 106923

18. “Establishment of a robust rat hepatitis E virus fecal-oral infection model and validation for antiviral Studies.” Antiviral Research (2023), 216, 105670

17. “Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models.” International Journal of Molecular Sciences (2023), 24(22), 16274

16. “Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles” National Center for Biotechnology Information – J Virol. 2023;97(10):e0072223

15. “Class a capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation.” Hepatology (2023)

14. “The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir.” mBio (2023), e0281522.

13. “Nomenclature of HBV core protein-targeting antivirals.” Nature Reviews Gastroenterology & Hepatology (2022), 19(12), 748.

12. “Opportunities and Challenges in Targeting the Proofreading Activity of SARS-CoV-2 Polymerase Complex.” Molecules (2022), 27(9), 2918.

11. “Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives.” Journal of Clinical Medicine (2022), 11(5), 1349.

10. “Mechanism of action of hepatitis B virus S antigen transport-inhibiting oligonucleotide polymer,STOPS, molecules.” Molecular Therapy–Nucleic Acids (2022), 27, 335-348.

9. “Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development.” Antiviral Research (2021), 187, 105020.

8. “Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).” PLoS One (2020), 15(12), e0240338.

7. “Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics.” PNAS (2021), 118(21), e2010718118.

6. “Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry.” SLAS Discovery (2021), 26(6), 766-774.

5. “Genome Sequences and Phylogeny of Two Duck Hepatitis B Viruses.” Microbiology Resource Announcements (2021), 10(7), e01327.

4. “Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting severe acute respiratory syndrome coronavirus 2 infection.” Current Opinion in Virology (2021), 49, 36-40.

3. “ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model.” Biochemical and Biophysical Research Communications (2021), 555, 134-139.

2. “Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.” Antiviral Research (2020), 182, 104924.

1. “Synthesis of Protected Amino Hexitol Nucleosides as Building Blocks for Oligonucleotide Synthesis.” Journal of Organic Chemistry (2018), 83(24), 15155.